IL6R and rheumatoid arthritis: Tocilizumab, a humanized anti-IL-6R antibody that binds both cell surfaces of IL-6R and soluble IL-6R, is approved for treatment of rheumatoid arthritis as well as systemic juvenile idiopathic arthritis and shows great promise against Crohn disease (18, 19).